In a recently published study by Yan et al. (2021), the authors found that in NSCLC patients, higher level of preoperative serum NSE predicted worse progression-free survival (PFS), with similar results in subsequent subgroup analysis of lung adenocarcinoma patients. This evidence concerns the gene ENO2 and non-small cell lung carcinoma.